Related Experiment Video

Updated: Jan 17, 2026

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.6K

Matrix Metalloproteinases and Their Inhibitors in Chronic Obstructive Pulmonary Disease

Zdenka Navratilova1, Vitezslav Kolek2, Martin Petrek3

  • 1Laboratory of Immunogenomics, Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 775 15, Olomouc, Czech Republic.

Archivum Immunologiae Et Therapiae Experimentalis
|November 28, 2015
PubMed

Insights

Chronic obstructive pulmonary disease (COPD) involves inflammation and airflow limitation. Dysregulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in COPD may offer new prognostic biomarkers for patient management.

Area of Science:

  • Pulmonary Medicine
  • Biochemistry

Background:

  • Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by chronic inflammation and irreversible airflow limitation.
  • Matrix metalloproteinases (MMPs) and their inhibitors, tissue inhibitors of metalloproteinases (TIMPs), play a crucial role in extracellular matrix remodeling and inflammatory processes.
  • The MMP/TIMP network, particularly MMP-9, is frequently dysregulated in COPD at both local and systemic levels.

Purpose of the Study:

  • To review findings on the MMP/TIMP network in human COPD studies, emphasizing longitudinal observations.
  • To explore the relationship between local lung and systemic MMP/TIMP networks in COPD patients.
  • To discuss the potential of the MMP/TIMP network as prognostic biomarkers and its role in COPD treatment.

Main Methods:

  • Review of numerous cross-sectional and longitudinal prospective studies on the MMP/TIMP network in COPD.
  • Analysis of data focusing on MMP-9 dysregulation in both local lung tissue and systemic circulation.
  • Inclusion of information on microRNA involvement and therapeutic implications.

Main Results:

  • Repeated observations of MMP/TIMP network dysregulation, especially MMP-9, in COPD patients.
  • Evidence suggesting potential for MMP/TIMP network components as novel prognostic biomarkers.
  • Insights into the interplay between local and systemic MMP/TIMP levels in COPD.

Conclusions:

  • Longitudinal data on the MMP/TIMP network in COPD may facilitate the development of new prognostic biomarkers.
  • Understanding the MMP/TIMP network is crucial for advancing the clinical management and treatment strategies for COPD.
Keywords:
BiomarkerChronic obstructive pulmonary diseaseLocal and systemic responseMatrix metalloproteinasesMicroRNAsTissue inhibitors of metalloproteinases

More Related Videos

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.5K
Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis07:52

Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis

Published on: December 21, 2014

10.5K

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.2K
Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult...
3.3K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.1K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.6K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.5K
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.3K